Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 18/20 | 0.54 |
| ▸ | HTR3A | P46098 | 3/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | HRH2 | P25021 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4953780 | 1.00 | HRH3 (0.54) | HRH3HTR3AKCNH2CHRM2SLC6A2 | |
| SCHEMBL4957830 | 0.99 | HRH3 (0.54) | HRH3HTR3AKCNH2CHRM2SLC6A2 | |
| SCHEMBL4955459 | 0.99 | HRH3 (0.54) | HRH3HTR3AKCNH2CHRM2SLC6A2 | |
| SCHEMBL4956767 | 0.98 | HRH3 (0.54) | HRH3HTR3AKCNH2CHRM2SLC6A2 | |
| SCHEMBL4955257 | 0.98 | HRH3 (0.54) | HRH3HTR3AKCNH2CHRM2SLC6A2 | |
| SCHEMBL4955710 | 0.89 | HRH3 (0.51) | HRH3HTR3AKCNH2CHRM2SLC6A2 | |
| SCHEMBL4955957 | 0.89 | HRH3 (0.50) | HRH3HTR3AKCNH2 | |
| SCHEMBL4955100 | 0.88 | HRH3 (0.47) | HRH3KCNH2CHRM2SLC6A2SLC6A3 | |
| SCHEMBL4956488 | 0.88 | HRH3 (0.47) | HRH3KCNH2CHRM2SLC6A2SLC6A3 | |
| SCHEMBL4953791 | 0.85 | HRH3 (0.53) | HRH3HTR3AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773345-B1 | NON-IMIDAZOLE TERTIARY AMINES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | ATHERSYS INC (US) | 2013-12-11 | — | — | EP | claimed |
| US-7319103-B2 | Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. (US) | 2008-01-15 | — | — | US | claimed |
| EP-1773345-A2 | NON-IMIDAZOLE TERTIARY AMINES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | Athersys, Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006004937-A2 | NON-IMIDAZOLE TERTIARY AMINES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | ATHERSYS, INC. (US) | 2006-01-12 | — | — | WO | claimed |
| US-20060009451-A1 | Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. | 2006-01-12 | — | — | US | claimed |
| EP-1773345-B1 | NON-IMIDAZOLE TERTIARY AMINES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | ATHERSYS INC (US) | 2013-12-11 | — | — | EP | disclosed |
| US-7319103-B2 | Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319103-B2 | Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. (US) | 2008-01-15 | — | — | US | disclosed |
| US-7319103-B2 | Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. (US) | 2008-01-15 | — | — | US | disclosed |
| EP-1773345-A2 | NON-IMIDAZOLE TERTIARY AMINES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | Athersys, Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006004937-A2 | NON-IMIDAZOLE TERTIARY AMINES AS HISTAMINE 3 RECEPTOR INHIBITORS FOR THE TREATMENT OF COGNITIVE AND SLEEP DISORDERS, OBESITY AND OTHER CNS DISORDERS | ATHERSYS, INC. (US) | 2006-01-12 | — | — | WO | disclosed |
| US-20060009451-A1 | Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | ATHERSYS, INC. | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009451-A1 | Non-imidazole tertiary amines as histamine 3 receptor inhibitors for the treatment of cognitive and sleep disorders, obesity and other CNS disorders | HRH3, HRH4, HRH1 | HRH3 1/4885HTR3A 15/4885KCNH2 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.